"Cardiotonic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
Descriptor ID |
D002316
|
MeSH Number(s) |
D27.505.954.411.222 D27.720.799.080
|
Concept/Terms |
Cardiotonic Agents- Cardiotonic Agents
- Cardiac Stimulants
- Inotropic Agents, Positive Cardiac
- Cardiotonic Drugs
- Cardiotonics
- Myocardial Stimulants
- Cardioprotective Agents
|
Below are MeSH descriptors whose meaning is more general than "Cardiotonic Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiotonic Agents".
This graph shows the total number of publications written about "Cardiotonic Agents" by people in this website by year, and whether "Cardiotonic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 0 | 2 |
1995 | 2 | 0 | 2 |
1996 | 1 | 1 | 2 |
1997 | 0 | 1 | 1 |
1999 | 2 | 0 | 2 |
2000 | 1 | 1 | 2 |
2001 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2003 | 0 | 3 | 3 |
2004 | 1 | 1 | 2 |
2005 | 3 | 3 | 6 |
2006 | 7 | 1 | 8 |
2007 | 2 | 3 | 5 |
2008 | 2 | 4 | 6 |
2009 | 2 | 2 | 4 |
2010 | 2 | 0 | 2 |
2011 | 2 | 4 | 6 |
2012 | 2 | 2 | 4 |
2013 | 2 | 5 | 7 |
2014 | 5 | 4 | 9 |
2015 | 4 | 3 | 7 |
2016 | 3 | 2 | 5 |
2017 | 2 | 0 | 2 |
2018 | 3 | 1 | 4 |
2019 | 5 | 4 | 9 |
2020 | 1 | 2 | 3 |
2021 | 0 | 2 | 2 |
2022 | 0 | 2 | 2 |
2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiotonic Agents" by people in Profiles.
-
Nonresponse to Heart?Failure?Therapy: An Important Trajectory. JACC Heart Fail. 2023 06; 11(6):729-732.
-
Milrinone therapeutic drug monitoring to reduce low cardiac output syndrome in pediatric patients. Can J Anaesth. 2023 05; 70(5):922-924.
-
Update on cardiogenic shock: from detection to team management. Curr Opin Cardiol. 2023 03 01; 38(2):108-115.
-
Milrinone or dobutamine in patients with heart failure: evidence from meta-analysis. ESC Heart Fail. 2022 06; 9(3):2049-2050.
-
A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents? Curr Cardiol Rep. 2022 06; 24(6):689-698.
-
Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis. Cardiol J. 2021; 28(3):492-493.
-
Venovenous Versus Venoarterial Extracorporeal Membranous Oxygenation in Inotrope Dependent Pediatric Patients With Respiratory Failure. ASAIO J. 2021 04 01; 67(4):457-462.
-
Commentary: Neonatal applications of cardiac cell therapy: It's good to be young! J Thorac Cardiovasc Surg. 2022 01; 163(1):248-249.
-
Survival With Continuous Outpatient Intravenous Inotrope Therapy in the Modern Era. Am J Ther. 2020 Oct 01; 28(6):e621-e630.
-
A systemic review on the antioxidant and anti-inflammatory effects of resveratrol, curcumin, and dietary nitric oxide supplementation on human cardiovascular health. Nutr Res. 2020 06; 78:11-26.